throbber
Contains Confidential Information
`Bound Separately
`
`Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`----------------------------------------------------------
` MYLAN PHARMACEUTICALS INC.,
` TEVA PHARMACEUTICALS USA,
` INC. and AKORN INC.,
` Petitioners,
` v.
` ALLERGAN, INC.
` Patent Owner.
` _____________________________
` Case IPR2016-01127 (US 8,685,930 B2)
` Case IPR2016-01128 (US 8,629,111 B2)
` Case IPR2016-01129 (US 8,624,556 B2)
` Case IPR2016-01130 (US 8,633,162 B2)
` Case IPR2016-01131 (US 8,648,048 B2)
` Case IPR2016-01132 (US 9,248,191 B2)
`
` CONTAINS CONFIDENTIAL INFORMATION - BOUND SEPARATELY
` DEPOSITION OF MAYSSA ATTAR
` Irvine, California
` Thursday, June 22, 2017
` Volume I
`
`Reported by:
`Gail E. Kennamer, CSR 4583, CCRR
`Job No. 125466
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`
`13
`
`14
`
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`MYLAN - EXHIBIT 1038
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 2
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`----------------------------------------------------------
` MYLAN PHARMACEUTICALS INC.,
` TEVA PHARMACEUTICALS USA,
` INC. and AKORN INC.,
` Petitioners,
` v.
` ALLERGAN, INC.
` Patent Owner.
` _____________________________
` Case IPR2016-01127 (US 8,685,930 B2)
` Case IPR2016-01128 (US 8,629,111 B2)
` Case IPR2016-01129 (US 8,624,556 B2)
` Case IPR2016-01130 (US 8,633,162 B2)
` Case IPR2016-01131 (US 8,648,048 B2)
` Case IPR2016-01132 (US 9,248,191 B2)
`
` Deposition of Mayssa Attar, Volume I
`taken on behalf of Petitioner at 3161 Michelson Drive,
`12th Floor, Irvine, California, beginning at 9:17 a.m.,
`and ending at 2:32 p.m., Thursday, June 22, 2017
`before Gail E. Kennamer, CSR 4583, CCRR.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`
`13
`
`14
`
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 3
`
`APPEARANCES:
`
`For Petitioner Mylan Pharmaceuticals, Inc.:
` WILSON SONSINI GOODRICH & ROSATI
` BY: JAD MILLS, ESQ.
` JACQUELINE ALTMAN, ESQ.
` 12235 El Camino Real
` San Diego, California 92130
`
`For Petitioner Teva Pharmaceuticals USA:
` CARLSON, CASPERS, VANDENBURGH,
` LINDQUIST & SCHUMAN
` BY: GARY SPEIER, ESQ. (Telephonic Appearance)
` 225 South Sixth Street
` Minneapolis, Minnesota 55402
`
`For Patent Owner:
` FISH & RICHARDSON
` BY: SUSAN MORRISON, ESQ.
` JONATHAN SINGER, ESQ.
` 222 Delaware Avenue
` Wilmington, Delaware 19801
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`
`2 3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 4
`
`APPEARANCES (Continued)
`
`Also Present:
` Dr. Daniel A. Bloch
` Ryan H. Coletti - Sr. Director
` Litigation Counsel for Allergan
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`
`2 3
`
`4
`5
`6
`
`7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
` INDEX
`WITNESS EXAMINATION
`MAYSSA ATTAR
`Volume I
`
`Page 5
`
` BY MR. MILLS 8, 170
` BY MS. MORRISON 166
`
`Questions the witness is instructed or refuses not to
`answer are located on the following pages:
` PAGE LINE
` 34 20
`
`Partial Confidential Transcript 43 to 45
`(Bound separately)
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`
`4 5
`
`6
`
`7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
` EXHIBITS
`NUMBER PAGE
`Exhibit 1033 LinkedIn Profile for 46
` Mayssa Attar
`
`Page 6
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`
`5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
` Irvine, California; Thursday, June 22, 2017
` 9:17 a.m.
`
`Page 7
`
` MAYSSA ATTAR,
`a witness herein, having been administered an oath, was
`examined, and testified as follows:
`
` THE REPORTER: Would counsel state their
`appearances, please.
` MR. MILLS: Jad Mills with Wilson, Sonsini on
`behalf of petitioner, Mylan Pharmaceuticals, Inc.
` With me I have Jacqueline Altman, also with Wilson,
`Sonsini; and I have Dr. Michael Bloch.
` MR. BLOCH: Correction. Daniel Bloch.
` MR. MILLS: Sorry. Thank you.
` MS. MORRISON: Susan Morrison from
`Fish & Richardson on behalf of Allergan and the witness.
` With me today is Jonathan Singer, also from
`Fish & Richardson; and Ryan Coletti from Allergan.
` THE REPORTER: Counsel, you may proceed.
` MR. MILLS: We have somebody on the phone.
` Could counsel on the phone please announce
`yourselves.
` MR. SPEIER: This is Gary Speier on behalf of
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`
`3 4
`
`5
`6
`
`7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Teva.
` THE REPORTER: Thank you.
` Counsel, you may proceed.
`
` -EXAMINATION-
`
`Page 8
`
` BY MR. MILLS:
` Q. Thank you.
` Please state your name for the record.
` A. Mayssa Attar.
` Q. And please state your place of business.
` A. Allergan.
` Q. Dr. Attar, do you understand why you're here
`today?
` A. Yes.
` Q. And why are you here today?
` A. So that I can be deposed.
` Q. Have you been deposed before?
` A. Yes.
` Q. How many times have you been deposed?
` A. Once.
` Q. Was that deposition in a patent case?
` A. Yes.
` Q. Did that deposition have anything to do with the
`subject matter of these IPR proceedings?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`
`4 5
`
`6 7
`
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 9
`
` A. No.
` Q. Do you understand what I say when I -- or what I
`mean when I say, "these IPR proceedings"?
` A. I know them to be distinct than the patent case.
`Yeah.
` Q. Okay. So I just want to make sure we're on the
`same page.
` A. Yes.
` Q. So there are six patents --
` A. Yes.
` Q. -- that are at issue; correct?
` A. Okay.
` Q. And there are -- There's an IPR proceeding for
`each of those six patents.
` A. Okay.
` Q. And those patents -- Do you know which patents
`those are?
` A. I -- I know -- Which patents are in the IPR
`proceedings? I know the Restasis patents, yes.
` Q. Okay. And you know what the six Restasis
`patents are that are at issue in the IPR proceedings?
` A. Yes, I do.
` Q. So if I refer to "the patents at issue," you'll
`know which patents I'm talking about?
` A. Yes.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 10
` Q. Okay. And if there's a specific patent that you
`want to talk about at some point, you can say, "Can we
`talk about this particular patent," if it matters --
` A. Sure.
` Q. -- if there's a difference.
` Okay. And you submitted declarations to the patent
`office in order to obtain the patents at issue in these
`IPR proceedings; correct?
` A. Correct.
` Q. Okay. Because you have only been deposed once
`before, I'm going to just talk a little bit about the
`ground rules in a deposition --
` A. Sure.
` Q. -- as a refresher.
` So we need to make sure we don't speak over each
`other. So it's difficult sometimes. You got to wait to
`make sure I finish my question before you start.
` A. Okay.
` Q. We need to make sure we try not to talk over
`each other so the court reporter can take down everything
`that we say.
` Do you understand?
` A. Okay. Yes.
` Q. It's also important that you give a verbal
`answer to my questions.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 11
`
` A. Okay.
` Q. You also understand that you are obligated by
`law to tell the truth to the questions that I ask you?
` A. Yes.
` Q. Okay. Is there any reason that you can't give
`your best testimony today?
` A. No.
` Q. Okay. When did you find out you would be
`deposed in the IPR proceedings?
` A. I would say about a month ago.
` Q. Have you done anything to prepare for your
`deposition today?
` A. I met with my lawyers yesterday.
` Q. Are those the three lawyers seated beside you?
` A. Just two of them, Susan and Jonathan.
` Q. Okay. For how long did you meet with the
`attorneys yesterday?
` A. I would say, roughly, two to three hours.
` Q. Did this meeting take place at Allergan?
` A. Yes.
` Q. Did you review any declarations as part of your
`preparation for your deposition today?
` A. Yes.
` Q. What declarations did you review?
` A. My own.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 12
` Q. How many of your own declarations did you review
`in preparation for your deposition today?
` A. Just one.
` Q. What patent was that declaration from?
` A. If I recall, sitting here today, it -- I don't
`know if it spoke to -- it called out specific patents, but
`it -- it spoke to the claims that I had reviewed, and
`those would be the ones that were -- would eventually get
`into the Restasis patents.
` Q. When you say the claims that you had reviewed,
`you mean the claims that you had reviewed in preparation
`for your declarations; correct?
` A. Yes.
` Q. And those claims include all of the claims in
`the six Restasis patents?
` A. Yes. Because I would have -- Yes.
` Q. I suppose what I'm trying to find out is you
`have several different declarations in each different
`patent file.
` A. Okay.
` Q. You reviewed one of those. Is that because --
` A. Yes.
` Q. -- the declarations are essentially identical?
` A. Yes.
` Q. Okay. So if we -- If I ask you questions today
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 13
`about one of those declarations, the answers would be the
`same --
` A. Yes.
` Q. -- with regard to the other declarations?
` A. Yes.
` THE REPORTER: Just remember to wait. I know
`it's hard. Thank you.
` THE WITNESS: Will do.
` BY MR. MILLS:
` Q. Other than your declarations, did you review any
`other declarations in preparation for your deposition
`today?
` A. Yes.
` Q. What documents were those?
` MS. MORRISON: Objection to the form.
` You can answer that. Lay a foundation.
` THE WITNESS: I reviewed -- I reviewed a
`publication.
` BY MR. MILLS:
` Q. Other than your declarations and one
`publication, did you review anything else in preparation
`for your deposition today?
` A. I -- I reviewed a study report.
` Q. And the study report is different than the
`publication?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 14
`
` A. Yes.
` Q. You only reviewed one study report?
` A. Yes.
` Q. So other than one of your declarations, one
`publication, one study report, did you review anything
`else in preparation for your deposition today?
` A. No.
` Q. What was the publication that you reviewed?
` A. It was a publication by Nussenblatt from -- I
`think it was from the '80s.
` Q. And why did you review the Nussenblatt
`publication?
` MS. MORRISON: Objection. That potentially
`calls for privileged communications.
` MR. MILLS: I'll limit my answer to
`non-privileged communications.
` MS. MORRISON: I don't think the substance of
`the -- I don't think the witness can answer the question
`without revealing the privileged communication.
` Maybe you want to ask a different question and see if
`you can lay a foundation.
` BY MR. MILLS:
` Q. Other than privileged information, are there any
`reasons that you reviewed the Nussenblatt publication in
`preparation for your deposition today?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 15
`
` A. No.
` Q. What was the study report that you reviewed in
`preparation for your deposition today?
` A. It was a study report for pharmacokinetic rabbit
`study after nine-and-a-half days of dosing. I believe the
`study number was 98-074, but that's my recollection. We
`would have to, you know, maybe go back and make sure
`that's the right number.
` Q. You reviewed that study report yesterday?
` A. Yes.
` Q. Was that the first time that you reviewed that
`study report?
` A. No.
` Q. When was the first time that you reviewed that
`study report?
` A. Probably sometime after 1999 when I joined
`Allergan was the first time.
` Q. You joined Allergan in 1999?
` A. Yes.
` Q. When you reviewed the PK Study 98-074 in
`preparation for your deposition today, did that refresh
`your recollection regarding anything?
` A. Yes.
` Q. In what ways did your review of the PK Study
`Report 98-074 refresh your recollection?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 16
`
` A. The study design.
` Q. Anything in particular regarding the study
`design?
` A. No. Just in general.
` Q. Other than the study design, did your review of
`the Study Report 98-074 refresh your recollection?
` A. No.
` Q. Other than your attorneys, you didn't speak with
`anyone in preparation for your deposition today; correct?
` A. Correct.
` Q. Have you ever spoken with Dr. Loftsson?
` A. No.
` Q. Have you ever spoken with Dr. Sheppard?
` A. No.
` Q. Do you know who Dr. Sheppard is?
` A. No.
` Q. Do you know who Dr. Loftsson?
` A. No.
` Q. Have you ever spoken with a Dr. Maness?
` A. No.
` Q. Do you know who Dr. Maness is?
` A. No.
` Q. Do you know Dr. Schiffman?
` A. Yes.
` Q. Have you ever spoken with Dr. Schiffman?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 17
`
` A. Yes.
` Q. Did you speak with Dr. Schiffman in preparation
`for your deposition today?
` A. No.
` Q. Did you speak with Dr. Schiffman while preparing
`your declarations?
` A. At the time that I was preparing the
`declaration, I believe Rhett was still an employee of the
`company. I might have spoken to him, but did I speak to
`him about the declaration? That, I don't recall, Rhett
`Schiffman.
` Q. Prior to submitting your declarations, did you
`speak with Rhett Schiffman regarding the subject matter of
`your declarations?
` MS. MORRISON: Objection to form.
` THE WITNESS: I can't recall.
` BY MR. MILLS:
` Q. As you sit here today, you don't recall ever
`speaking with Rhett Schiffman -- Rhett Schiffman prior to
`filing your declarations regarding the subject matter of
`those declarations?
` A. So certainly, we had been working for a long
`time about the pharmacokinetics and how you develop
`cyclosporin therapies, so the subject matter we would have
`discussed, yes. And did we discuss it specifically as it
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 18
`relates to the declaration, I can't recall right now.
` Q. What types of discussions would you have had
`with Dr. Schiffman regarding the subject matter of the
`declarations?
` A. I can't recall.
` Q. You mentioned that you were deposed before in a
`patent case. What case was that?
` A. What I -- What I know was the patent case
`related to Restasis.
` Q. So you've been deposed once before, and that was
`in a patent case related to Restasis; correct?
` A. Yes.
` Q. And that's the same commercial product that's at
`issue in these IPR proceedings; correct?
` A. Correct.
` Q. And is it your understanding that that is a
`District Court case?
` A. It is -- So what would I say to that? I guess
`so.
` Q. In your deposition in the District Court case,
`did you rely on information that was available in the
`District Court case that's not available in these IPR
`proceedings?
` MS. MORRISON: Objection to the form.
` THE WITNESS: I don't think so.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 19
`
` BY MR. MILLS:
` Q. Are you relying for your opinions in these IPR
`proceedings on any information that was available in the
`District Court case, but is not available in the IPR
`proceeding?
` MS. MORRISON: Objection to the form.
` THE WITNESS: Can you repeat the question?
` BY MR. MILLS:
` Q. Sure.
` Are you relying for your opinions in these IPR
`proceedings on any information that was available in the
`District Court case that is not available in the IPR
`proceedings?
` MS. MORRISON: Objection to the form.
` THE WITNESS: I don't think so.
` BY MR. MILLS:
` Q. You mentioned that you began your work at
`Allergan in 1999; correct?
` A. Correct.
` Q. You have been employed at Allergan for
`18-and-a-half years?
` A. Correct.
` Q. And what is your current position at Allergan?
` A. Associate vice president.
` Q. When you began at Allergan 18-and-a-half years
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 20
`
`ago, you were thought an associate vice president;
`correct?
` A. Correct.
` Q. You began as an associate professional?
` A. Correct.
` Q. What is an associate professional?
` A. It is a lab technician.
` Q. How long were you a lab technician at Allergan?
` A. Let's see here. I would say five to six years,
`roughly.
` Q. Who was your supervisor when you were an
`associate professional at Allergan?
` A. John Ling.
` Q. Can you spell the last name?
` A. Sure. L-i-n-g.
` Q. After five to six years as an associate
`professional, what was your next title at Allergan?
` A. Scientist. Oh, I'm sorry. As a lab technician,
`I was an associate professional, a professional, and then
`a senior professional.
` Q. And your five to six years as a lab tech, does
`that include all three positions that included the word
`professional?
` A. Yes.
` Q. Okay. And in each of those positions, was your
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 21
`
`supervisor John Ling?
` A. I believe so.
` Q. Did you have any other supervisors at the time
`that you were a professional -- had the professional title
`at Allergan?
` A. I might have had at one point somebody called
`Allison Vickers.
` Q. Can you spell the last name?
` A. Sure.
` V-i-c-k-e-r-s.
` Q. Thank you.
` Anyone else?
` A. No.
` Q. After your position as a senior professional at
`Allergan, you said then you had the job title of
`scientist?
` A. Yes.
` Q. And what is the difference between the job
`responsibilities of a professional versus a scientist?
` A. So a professional was the studies were designed
`primarily by Ph.D.-level scientists, and I had that job
`before I had a Ph.D.
` And then when I got a Ph.D., I became a scientist,
`then I would design the studies myself.
` Q. You were a non-Ph.D. professional from
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 22
`approximately 1999 through 2005 at Allergan; correct?
` A. Correct.
` Q. Beginning in approximately 2005, you received
`your Ph.D. and became a scientist at Allergan; correct?
` A. Correct.
` Q. How long did you remain a scientist at Allergan?
` A. Roughly, one to two years.
` Q. Until approximately 2007?
` A. Yes.
` Q. And at all time points when you were a
`scientist, was your job title simply scientist or were
`there other additions to the title?
` A. That was it.
` Q. What was your next position after being a
`scientist?
` A. Senior scientist.
` Q. Okay. And during what time period were you a
`senior scientist at Allergan?
` A. I would say, again, roughly, let's say, two to
`three years.
` Q. So that was from approximately 2007 to 2010?
` A. Approximately.
` Q. You mentioned that you received your Ph.D. while
`you were working at Allergan; correct?
` A. Correct.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 23
` Q. Did Allergan support you in obtaining your
`Ph.D.?
` MS. MORRISON: Objection to form.
` THE WITNESS: While I was obtaining my Ph.D., I
`was -- my working hours were accommodated to be able to go
`to school.
` BY MR. MILLS:
` Q. Other than accommodating your working hours, did
`Allergan provide you with any other support to obtain your
`Ph.D.?
` A. Not really.
` Q. Who was your supervisor at Allergan when you
`held the title of scientist?
` A. So it was Allison Vickers, and at some point I
`transitioned to somebody called Devin Welty.
` Q. Who was your supervisor when your job title was
`senior scientist?
` A. Devin Welty.
` Q. Anyone else?
` A. No.
` Q. After you left the title of senior scientist,
`what was your next job title?
` A. Principal scientist.
` Q. What's the difference between a principal
`scientist and a senior scientist?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 24
` A. I think the best way to describe it is you have
`more autonomy on a project to, say, put together a series
`of studies and how that would answer, you know -- or how
`that would support the overall development of the drug.
` Q. When you are referring to more autonomy on a
`project, are you referring to preclinical studies?
` A. At the point, yes.
` Q. Through the time period in which you were a
`principal scientist, your work at Allergan was limited to
`exclusive preclinical studies; correct?
` A. Correct.
` Q. That would include preclinical pharmacokinetic
`studies?
` A. Yes.
` I'd like to though -- I wouldn't use the word
`preclinical as much as nonclinical, and I'll tell you why.
`Because there might have been a version that we would take
`clinical samples and work at the bench, and so it's not so
`nonclinical.
` Q. And when you say "nonclinical," what you mean is
`that it's not a human trial; correct?
` A. Yes. You're not actively involved in a human
`trial.
` Q. During your time at Allergan, up until you --
`and through the time that you were a principal scientist,
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 25
`were you involved personally in any clinical trials at
`Allergan?
` A. I was not an active study team member, to the
`best of my recollection.
` Q. That means that you were not a participant in
`the clinical trials of Restasis; correct?
` A. Correct.
` Q. Have you ever participated in a clinical trial?
` A. Yes.
` Q. When was the first time you participated in a
`clinical trial?
` A. So as an active study team member on an ongoing
`clinical trial, I would say -- because, like I said, I was
`involved in non- -- nonclinical activities on active
`clinical trials, but where I was actually part of
`reviewing protocols, signing off on things, I would say
`that's going to be around 2014.
` Q. And what was your position in 2014 when you
`first participated actively in a clinical trial?
` A. Director.
` Q. And was that your next position after principal
`scientist?
` A. Yes.
` Q. And just for completeness, during what years
`were you a principal scientist at Allergan?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 26
` A. Again, it would have been two to three years.
` Q. So that's approximately 2010 through 2013?
` A. I'm thinking.
` That's exactly right, yeah, approximately.
` Q. And then you became a director at Allergan in
`approximately 2013?
` A. Yes.
` Can I make a clarification?
` Q. Sure.
` A. It's -- Well, it's -- So director, we had
`multiple reorganizations. So it was the same essential
`job, but it had the title of director, scientific
`director, and research investigator. For completeness.
` Q. Okay. And just to be clear, that's a different
`job than principal scientist; correct?
` A. Yes.
` Q. So beginning in 2013, you held a different job
`than being a principal scientist, which was sometimes
`called director, sometimes scientific director, and
`sometimes research investigator?
` A. Yes. Approximately, 2013.
` Q. And how long did you hold that job?
` A. Until mid-2014.
` Q. And what was the difference in your job
`responsibilities in the director role as opposed to
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 27
`
`principal scientist role?
` A. So in the director role, I had multiple Ph.D.
`scientists that were -- that were overseeing programs
`themselves reporting to me directly.
` Q. At that point, were you directly designing the
`studies?
` A. I was -- I'm trying to think, did I have any
`projects of my own at that time. I -- I don't think I was
`directly the one designing at that point.
` Q. Beginning in 2013, you moved from designing the
`projects to approving the projects designed by others;
`correct?
` A. Yes.
` Q. Going back to when you were principal scientist,
`who was your supervisor at Allergan?
` A. So it began as Devin Welty.
` And then became Tim Maziasz.
` Q. Can you spell the last name, please?
` A. Sure. M-a-z-i-s- -- i-a-s-z.
` Q. M-a-z-i-a-s-z?
` A. Maziasz, yeah.
` Q. And, then, who was your supervisor when you were
`a director at Allergan?
` A. It began as Tim Maziasz; then it went to Ron Li,
`L-i; and then it went to Gabriella Szekely.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 28
`
` Q. Can you spell the last name, please.
` A. Sure. S-z-e-k-e-l-y.
` Q. You said that you ceased being a director in
`mid-2014; correct?
` A. Correct.
` Q. What was your next job title at Allergan?
` A. Senior director.
` Q. And what was the difference between your
`responsibilities as a senior director as compared to when
`you were a director?
` A. I had an expanded group, a larger group, and
`then expanded scope of responsibility.
` Q. When you say "an expanded scope of
`responsibility," what do you mean by that?
` A. So by that point, all nonclinical and clinical
`pharmacokinetics reported in to me. Pretty sure it was
`all at that point.
` Q. That's why as a senior director, you began
`participating personally in clinical studies?
` A. Exactly.
` Q. And who was your supervisor when you were senior
`director at Allergan?
` A. It began as Gabriella Szekely, and then became
`Paul Trennery.
` Q. How long were you a senior director at Allergan?
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 29
`
` A. Until January of this year.
` Q. January 2017; correct?
` A. Correct.
` Q. At that point, you became an associate vice
`president?
` A. Yes.
` Q. What were the differences between your job
`responsibilities as associate vice president as compared
`to when you were a senior director?
` A. Yes. Okay. So my -- my responsibilities as a
`senior director evolved over time, and they continued to
`be my responsibilities as an associate vice president, so
`I will explain that.
` So I -- I had, as I have already stated, the
`nonclinical and the clinical pharmacokinetics, and then I
`also had an ADME group as well as an immunology group.
` Q. Can you explain what an ADME group is?
` A. Sure.
` ADME stands for absorption, distribution, metabolism,
`elimination. And so this is a group of bench scientists
`that predominantly run in vitro studies to support
`pharmacokinetic assessments.
` Q. So that's ADME; correct?
` A. Exactly.
` Q. And does the ADME roughly correspond to what you
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 30
`
`were doing as a director and previous to then?
` MS. MORRISON: Objection to form.
` THE WITNESS: ADME is a supporting science, an
`integral part of pharmacokinetics, yeah.
` BY MR. MILLS:
` Q. Then you mentioned you also had responsibilities
`with immunology?
` A. Yes.
` Q. Can you tell us what those were?
` A. I had an immunology group that had its own group
`head, and their responsibility was predominantly to
`develop immunoassays.
` Q. And in your role as associate vice president,
`did you supervise the development of immunoassays for use
`in relationship to Restasis?
` A. I did not.
` Q. Other than filing your declarations with the
`patent office, did you have any other involvement with
`Restasis during your career at Allergan?
` MS. MORRISON: Objection to the form.
` THE WITNESS: I was a project representative.
` BY MR. MILLS:
` Q. When were you a project representative for
`Restasis?
` A. So let me take that back. Restasis was approved
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Contains Confidential Information
`Bound Separately
`
`Page 31
`by the time I was a project representative. So what I
`was, is for follow-ons to Restasis; so that's probably
`different.
` Q. Okay. So what is a project representative?
` A. So the way drugs are developed, you have
`multiple functions represented in a team, and I would
`represent pharmacokinetics.
` Q. Okay. And in what years were you a project
`representative for the Restasis follow-ons?
` A. From 200

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket